Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ERN1 | O75460 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 1/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27845620 | 0.78 | LTA4H (0.55) | LTA4HERN1CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL27845623 | 0.78 | LTA4H (0.55) | LTA4HERN1CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL338810 | 0.77 | LTA4H (0.70) | LTA4HERN1CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL28774170 | 0.75 | CYP3A4 (0.47) | ERN1CYP3A4TSHRKDM4EALDH1A1 | |
| SCHEMBL23721668 | 0.75 | CYP3A4 (0.61) | CYP3A4TSHRMEN1ALDH1A1HPGD | |
| SCHEMBL241534 | 0.75 | CYP3A4 (0.61) | CYP3A4TSHRMEN1ALDH1A1HPGD | |
| SCHEMBL7455134 | 0.75 | LTA4H (0.67) | LTA4HERN1CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL2552117 | 0.75 | LTA4H (0.52) | LTA4HERN1CYP3A4CYP17A1CYP11B1 | |
| SCHEMBL5578421 | 0.73 | LTA4H (0.50) | LTA4HERN1CYP3A4TSHRCYP17A1 | |
| Hydrogen Sulfide SCHEMBL3894665 | 0.73 | CYP3A4 (0.58) | CYP3A4TSHRMEN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643397-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2023-05-09 | — | — | US | disclosed |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2021-11-11 | — | — | US | disclosed |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2020-05-21 | — | — | US | disclosed |
| EP-3296309-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC (US) | 2018-10-25 | — | — | US | disclosed |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | GlaxoSmithKline, LLC (US) | 2018-07-31 | — | — | US | disclosed |
| EP-3296309-A1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | Universiteit Gent (BE) | 2018-03-21 | — | — | EP | disclosed |
| EP-2877480-B1 | GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS | UNIV GENT (BE) | 2017-09-06 | — | — | EP | disclosed |
| WO-2009003669-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-01-08 | — | — | WO | disclosed |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | UNIBIOSCREEN S.A. (BE) | 2008-11-27 | — | — | US | disclosed |
| EP-1981504-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV Remynd (BE) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
| EP-1960365-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | Unibioscreen S.A. (BE) | 2008-08-27 | — | — | EP | disclosed |
| WO-2008061781-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO-DEGENERATIVE DISEASES | NV REMYND (BE) | 2008-05-29 | — | — | WO | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
| WO-2007150011-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007090617-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007054292-A2 | AZONAFIDE DERIVATIVES, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THEREFROM | UNIBIOSCREEN S.A. (BE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643397-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | LTA4H 1580/4885ERN1 2435/4885CYP3A4 1254/4885 |
| US-20210347740-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | LTA4H 1580/4885ERN1 2435/4885CYP3A4 1254/4885 |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | LTA4H 2529/4885ERN1 1310/4885CYP3A4 377/4885 |
| US-10336711-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | LTA4H 1580/4885ERN1 2435/4885CYP3A4 1254/4885 |
| US-20080292585-A1 | Azonafide Derivatives, Methods for Their Production and Pharmaceutical Compositions Therefrom | AADAC, NOTUM, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | LTA4H 1341/4885ERN1 4761/4885CYP3A4 187/4885 |
| US-20200157055-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | LTA4H 1580/4885ERN1 2435/4885CYP3A4 1254/4885 |
| US-20180305323-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | LTA4H 1580/4885ERN1 2435/4885CYP3A4 1254/4885 |
| US-10035779-B2 | Prolyl hydroxylase inhibitors | HIF1AN, EGLN3, EGLN2 | LTA4H 1580/4885ERN1 2435/4885CYP3A4 1254/4885 |
| US-20230227414-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | LTA4H 1580/4885ERN1 2435/4885CYP3A4 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.